ARWR (Arrowhead Pharmaceuticals) LT-Debt-to-Total-Asset: 0.42 (As of Mar. 2026)

What is Arrowhead Pharmaceuticals LT-Debt-to-Total-Asset?

Arrowhead Pharmaceuticals ARWR -0.46% 49 LT-Debt-to-Total-Asset is 0.42 as of Mar. 2026. GuruFocus rates ARWR with a GF Score™ of 49/100 and a GF Value™ of $52.13 (Significantly Overvalued). The stock has 7 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Arrowhead Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.42.

Arrowhead Pharmaceuticals's long-term debt to total assets ratio increased from Mar. 2025 (0.20) to Mar. 2026 (0.42). It may suggest that Arrowhead Pharmaceuticals is progressively becoming more dependent on debt to grow their business.

Arrowhead Pharmaceuticals (NAS:ARWR) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Arrowhead Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Arrowhead Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Arrowhead Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arrowhead Pharmaceuticals LT-Debt-to-Total-Asset Chart

Arrowhead Pharmaceuticals Annual Data

Trend

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Sep25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.03

0.11

0.14

0.44

0.23

Arrowhead Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.20	0.22	0.23	0.17	0.42

49GF Score

Arrowhead Pharmaceuticals Inc ARWR

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Arrowhead Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Arrowhead Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Sep. 2025 is calculated as

LT Debt to Total Assets (A: Sep. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Sep. 2025 )	/	Total Assets (A: Sep. 2025 )
	=	318.995	/	1385.295
	=	0.23

Arrowhead Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	941.685	/	2268.265
	=	0.42

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.42 mean?

Arrowhead Pharmaceuticals (ARWR) has a LT-Debt-to-Total-Asset of 0.42 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Arrowhead Pharmaceuticals and its competitors.

Is Arrowhead Pharmaceuticals' LT-Debt-to-Total-Asset too high?

Arrowhead Pharmaceuticals' current LT-Debt-to-Total-Asset is 0.42. Overall, Arrowhead Pharmaceuticals has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Arrowhead Pharmaceuticals' LT-Debt-to-Total-Asset compare to CYTK and TECH?

Arrowhead Pharmaceuticals' LT-Debt-to-Total-Asset of 0.42 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Arrowhead Pharmaceuticals and its competitors. Arrowhead Pharmaceuticals's current LT-Debt-to-Total-Asset is 0.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Arrowhead Pharmaceuticals stock overvalued right now?

Based on GuruFocus' analysis, Arrowhead Pharmaceuticals (ARWR) is currently considered Significantly Overvalued. The stock's GF Value™ is $52.13, compared to a current price of $80.13 — trading 53.7% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.42. Arrowhead Pharmaceuticals' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Arrowhead Pharmaceuticals (ARWR), the current LT-Debt-to-Total-Asset is 0.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arrowhead Pharmaceuticals (ARWR) Overvalued in 2026?

Based on GuruFocus' analysis, Arrowhead Pharmaceuticals stock appears to be overvalued. The current stock price of $80.13 is trading 53.7% above its estimated GF Value™ of $52.13. GuruFocus considers Arrowhead Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for ARWR:

LT-Debt-to-Total-Asset: 0.42
GF Value™: $52.13 vs. price of $80.13 (53.7% above fair value)
GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the ARWR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arrowhead Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies CYTK TECH KRYS SMMT BMRN MDGL APGE AXSM NUVL CORT VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges 0HI3:UK HDP1:Germany A2RR34:Brazil

Address 177 E Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105

Website https://www.arrowheadpharma.com

Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.

49GF Score

Get the complete analysis for ARWR

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$80.13

Price

$52.13

GF Value

View ARWR Analysis

See LT-Debt-to-Total-Asset data for all stocks →